Oppenheimer Asset Management Inc. Reduces Stake in Takeda Pharmaceutical Co. (NYSE:TAK)

Oppenheimer Asset Management Inc. lessened its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 6.1% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 55,466 shares of the company’s stock after selling 3,585 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Takeda Pharmaceutical were worth $825,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in Takeda Pharmaceutical in the 1st quarter worth approximately $37,000. Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 123.6% in the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. purchased a new stake in Takeda Pharmaceutical in the 4th quarter worth approximately $52,000. Lindbrook Capital LLC boosted its position in Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company’s stock worth $68,000 after purchasing an additional 2,029 shares in the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in Takeda Pharmaceutical by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company’s stock worth $69,000 after purchasing an additional 1,770 shares in the last quarter. Hedge funds and other institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.3%

Shares of TAK stock opened at $15.11 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.01 and a quick ratio of 0.52. The company has a market cap of $48.06 billion, a price-to-earnings ratio of 68.66 and a beta of 0.23. The stock has a 50 day simple moving average of $14.83 and a 200-day simple moving average of $14.25. Takeda Pharmaceutical Co. has a 1-year low of $12.80 and a 1-year high of $15.43.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings data on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Takeda Pharmaceutical had a net margin of 2.36% and a return on equity of 10.64%. On average, equities research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an “equal weight” rating to an “overweight” rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.